本帖最后由 老马 于 2013-3-13 13:43 编辑
) S; j% x0 x5 e& {% h' U- x) a4 r" `8 w m
健择（吉西他滨）+顺铂+阿瓦斯汀' j# _# g. v* Q# C/ m4 G! p4 _( n
Gemzar +Cisplatin + Avastin' q( g" M! c. f* h8 D' Q
http://annonc.oxfordjournals.org/content/21/9/1804.full
( `0 i' t" Q4 a/ P. vOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) . O9 f; p( G1 R1 m3 N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 q1 }4 l- h. j8 ~2 Y8 CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( Z5 r4 p3 Q; ]0 p
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1060)
! y$ ]: m8 G7 D& |' [
华为网盘附件：" X5 v% @4 _! V! ~$ m2 D9 h
【华为网盘】ava.JPG
; s& T0 t. Y/ D, b |
显身卡
